AstraZeneca exercises final option to develop brensocatib in COPD/asthma

INSMED Inc

AstraZeneca exercised second option under 2016 license to develop brensocatib in COPD or asthma beyond Phase 2b.
Final commercialization terms subject to good faith negotiation; no financial details disclosed.
Insmed retains full rights to brensocatib in all other indications.
Brensocatib is a DPP1 inhibitor for neutrophil-mediated diseases; AstraZeneca already had first option.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.